The fate of Hancock II porcine valve recipients 25 years after implant☆

Valfré, Carlo; Ius, Paolo; Minniti, Giuseppe; Salvador, Loris; Bottio, Tomaso; Cesari, Francesco; Rizzoli, Giulio; Gerosa, Gino

doi:10.1016/j.ejcts.2010.01.046

Cited by 59 publications

(34 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Late survival rates can be considered acceptable, given the old age of most patients at time of operation (>20% of them were 80 years or older); these data are similar to those reported on the Hancock II bioprosthesis in the mitral position by Valfrè and colleagues, 5 who observed a 39% survival rate at 15 years; and they are comparable with those reported by Riess and colleagues 10 at 13 years, after MVR with the MB in a smaller sample of patients. We have observed a substantially low incidence of thromboembolic episodes (0.65% ± 0.33% per pt-yr), with an actuarial freedom from this sequela of 91% ± 5% at 15 years, and a negligible rate of anticoagulant-related hemorrhages.…”

Section: Discussionsupporting

confidence: 72%

“…1,2 Since that time, the use of calcium-retarding agents to mitigate the severity of cusp mineralization has given longer durability to most commercially available tissue valves. [3][4][5] The Mosaic ® bioprosthesis (MB) (Medtronic, Inc.; Minneapolis, Minn) is a 3rd-generation porcine valve that became clinically available in 1994. Various reports [6][7][8][9] have shown that the MB is a safe and well-performing device in the medium and intermediate terms.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Mosaic Mitral Valve Bioprosthesis: A Long-Term Clinical and Hemodynamic Follow-Up

Celiento¹,

Blasi²,

Martino³

et al. 2016

Texas Heart Institute Journal

View full text Add to dashboard Cite

We reviewed the cases of 100 patients (mean age, 73 ± 10 yr; 64 men) who had mitral valve replacement with a Medtronic Mosaic porcine bioprosthesis from 1995 through 2011. The mean New York Heart Association (NYHA) class was 3 ± 0.7, and 52 patients were in atrial fibrillation. Prosthetic sizes were chiefly 27 mm (50 patients) and 29 mm (40 patients). Follow-up ended in December 2012 and is 97% complete, with a cumulative duration of 611 patient-years (mean duration, 6 ± 4.6 yr; maximum, 17.7 yr). The early mortality rate was 10% (6% in elective patients); late deaths occurred in 31 patients (5 valve-related). Actuarial survival rates at 5, 10, and 15 years were 74% ± 5%, 50% ± 6%, and 37% ± 8%. The mean NYHA class in survivors was 1.4 ± 0.6 (P <0.0001). Thromboembolic episodes occurred in 4 patients, with an actuarial freedom at 15 years of 91% ± 5%. No cases of endocarditis were observed. Four patients needed reoperation, 2 for structural failure, and 1 each for perivalvular leakage and valve thrombosis. Actuarial freedom from structural failure and from reoperation, respectively, was 93% ± 5% and 91% ± 5% at 15 years. Echocardiographic follow-up in 24 patients with 27-mm prostheses showed a mean gradient of 5 ± 1.7 mmHg and an effective orifice area of 1.57 ± 0.3 cm2; in 16 patients with 29-mm prostheses, the mean gradient was 4.5 ± 1.9 mmHg, and the effective orifice area, 1.63 ± 0.4 cm2. During nearly 17 years of follow-up, the Mosaic bioprosthesis has shown good overall clinical and hemodynamic performance after mitral valve replacement.

show abstract

Section: Discussionsupporting

confidence: 72%

mentioning

confidence: 99%

The Mosaic Mitral Valve Bioprosthesis: A Long-Term Clinical and Hemodynamic Follow-Up

Celiento¹,

Blasi²,

Martino³

et al. 2016

Texas Heart Institute Journal

View full text Add to dashboard Cite

show abstract

“…The Hancock II valve was a second-generation porcine valve introduced in 1982. Results in terms of freedom from SVD when placed in the mitral position were comparable to that of the Hancock I [6].…”

supporting

confidence: 64%

Acute Decompensated Heart Failure Secondary to Structural Valve Degeneration of a Bioprosthetic Valve

Mehaffey¹,

Cantor²

2014

OJAnes

View full text Add to dashboard Cite

Heart valve replacement is a common cardiac surgical procedure used to treat native valvular diseases such as aortic and mitral stenosis and regurgitation. These procedures reduce the morbidity and mortality associated with diseased native valves and yet come at the expense of prosthetic valve complications. Structural valve degeneration is one such complication. We present a case of a critically ill elderly man who had undergone mitral valve replacement 14 years prior to his current presentation. Only after admission through the emergency department was a transesophageal echocardiogram obtained and the diagnosis of prosthetic valve degeneration made. He subsequently underwent successful replacement of his diseased prosthetic valve.

show abstract

“…3). 7,59 Similar to the other bioprosthetic valves, the hemodynamics are vastly improved over those of mechanical valves.…”

Section: Bioprosthetic Mitral Valvesmentioning

confidence: 91%

Emerging Trends in Heart Valve Engineering: Part III. Novel Technologies for Mitral Valve Repair and Replacement

et al. 2014

View full text Add to dashboard Cite

Abstract-In this portion of an extensive review of heart valve engineering, we focus on the current and emerging technologies and techniques to repair or replace the mitral valve. We begin with a discussion of the currently available mechanical and bioprosthetic mitral valves followed by the rationale and limitations of current surgical mitral annuloplasty methods; a discussion of the technique of neo-chordae fabrication and implantation; a review the procedures and clinical results for catheter-based mitral leaflet repair; a highlight of the motivation for and limitations of catheterbased annular reduction therapies; and introduce the early generation devices for catheter-based mitral valve replacement.

show abstract

The fate of Hancock II porcine valve recipients 25 years after implant☆

Abstract: These results confirm the excellent long-term performance of the HII bioprosthesis.

Cited by 59 publications

References 13 publications

The Mosaic Mitral Valve Bioprosthesis: A Long-Term Clinical and Hemodynamic Follow-Up

The Mosaic Mitral Valve Bioprosthesis: A Long-Term Clinical and Hemodynamic Follow-Up

Acute Decompensated Heart Failure Secondary to Structural Valve Degeneration of a Bioprosthetic Valve

Emerging Trends in Heart Valve Engineering: Part III. Novel Technologies for Mitral Valve Repair and Replacement

Contact Info

Product

Resources

About